Dosing

Taltz dosing for adult patients with moderate to severe plaque psoriasis1

The dosing regimen is the same for adult patients with moderate to severe plaque psoriasis and for adult patients with psoriatic arthritis* and coexistent moderate to severe plaque psoriasis

Taltz dosing for plaque psoriasis


Reminders1,5

  • If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then to take their next dose at the regularly scheduled time

For detailed administration instructions, please have patients read the Instructions for Use included with the device.

TALTZ is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in the proper technique. Evaluate patients for tuberculosis prior to initiating treatment with TALTZ.

Taltz dosing for adult patients with psoriatic arthritis1

Taltz dosing for psoriatic arthritis

For patients with psoriatic arthritis and coexistent moderate to severe plaque psoriasis, follow the plaque psoriasis dosing.

If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then to take their next dose at the regularly scheduled time.

For detailed administration instructions, please have patients read the Instructions for Use included with the device.

TALTZ is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in the proper technique. Evaluate patients for tuberculosis prior to initiating treatment with TALTZ.

Just a 1-day starting dose followed by a once-monthly* schedule

Taltz dosing for ankylosing spondylitis

*Every 4 weeks.

Starting dose of two 80 mg injections, followed by one 80 mg injection every 4 weeks thereafter.

The dosing regimen is the same for adult patients with ankylosing spondylitis and for adult patients with psoriatic arthritis without coexistent moderate to severe plaque psoriasis.

If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then, to take their next dose at the regularly scheduled time.

TALTZ is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in the proper technique. Evaluate patients for tuberculosis prior to initiating treatment with TALTZ.

FOR PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz pediatric PsO dosing1

Taltz dosing for pediatric psoriasis is based on a patient’s weight.

In some cases, prefilled Taltz 80 mg dose must be adjusted based on weight, and then administered using a new disposable syringe, with the unused portion of Taltz discarded. Be sure to follow the dosing regimen outlined below as well as the instructions below for preparing tailored, weight-based dosing.

Taltz dosing for pediatric psoriasis

Q4W=every 4 weeks

If patients miss a dose, instruct them to receive a dose as soon as they remember, then to receive their next dose at their regularly scheduled time.

SELECT IMPORTANT ADMINISTRATION INFORMATION: PEDIATRIC PSORIASIS
Advise the patient and/or caregiver to read Medication Guide and Instructions for Use before the patient starts using Taltz, and each time the prescription is renewed, as there may be new information they need to know.

Taltz is intended for use under the guidance and supervision of a physician. Adult patients may self-inject or caregivers may give injections of 80 mg Taltz after training in subcutaneous injection technique using the autoinjector or prefilled syringe. Taltz doses of 20 mg or 40 mg must be prepared and administered by a qualified healthcare provider using aseptic technique.

Instructions on Self-Administration: Provide guidance to patients and caregivers on proper subcutaneous injection technique, including aseptic technique, and how to use the autoinjector or prefilled syringe correctly. Caregivers may give injections to pediatric patients weighing more than 50 kg using the autoinjector or prefilled syringe after training and demonstration of proper subcutaneous injection technique.

Devices



Taltz has 2 device options, offering you the flexibility to choose the one that best suits your patients1,6

Devices designed with patients in mind

Dosing devices

At first use, over 94% of patients with moderate to severe plaque psoriasis agreed the Taltz autoinjector was “easy to use” and were confident in their ability to use it.

Please see Instructions for Use included with the device.

Device study trial design

Pediatric PsO Dosing Preparation


References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 2. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013:133:17-26. 3. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2013;141:133-142. 4. Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178:1003-1005. 5. Taltz [instructions for use]. Indianapolis, IN: Eli Lilly and Company; 2018. 6. Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361-369.

Indications and Important Safety Information
Indications

Taltz is indicated for patients as young as age 6 with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adult patients with active psoriatic arthritis (PsA). Taltz is also indicated for adult patients with active ankylosing spondylitis (AS).

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis and ankylosing spondylitis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis and ankylosing spondylitis and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 26MAR2020